Kiora Pharmaceuticals Inc
Change company Symbol lookup
Select an option...
KPRX Kiora Pharmaceuticals Inc
AAPL Apple Inc
GWRE Guidewire Software Inc
NXGN NextGen Healthcare Inc
NB NioCorp Developments Ltd
O Realty Income Corp
BB BlackBerry Ltd
AL Air Lease Corp
VICI VICI Properties Inc
PWR Quanta Services Inc

Health Care : Pharmaceuticals | Small Cap Value
Company profile

Kiora Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is focused on developing and commercializing therapies for the treatment of ophthalmic diseases. Its pipeline consists of three product candidates, including KIO-101, KIO-301, and KIO-201. Its lead product, KIO-301, is a potential vision-restoring small molecule that is designed to restore vision in patients with inherited and age-related degenerative retinal diseases. KIO-101 is a non-steroidal, immuno-modulatory, small-molecule inhibitor of Dihydroorotate Dehydrogenase (DHODH) that focuses on patients with Ocular Presentation of Rheumatoid Arthritis (OPRA). Its KIO-201 is a synthetic modified hyaluronic acid (HA) capable of coating the ocular surface and designed to resist degradation under conditions present in the eye. Its wholly owned subsidiaries include Jade Therapeutics, Inc., Kiora Pharmaceuticals, GmbH, Bayon Therapeutics, Inc. and Kiora Pharmaceuticals Pty Ltd.

Day's Change
0.1255 (3.78%)
B/A Size
Day's High
Day's Low
(Above Average)

Today's volume of 44,903 shares is on pace to be greater than KPRX's 10-day average volume of 57,547 shares.

  • Prev Close
  • Today's Open
  • Day's Range
  • Avg Vol (10-day)
  • Last (time)
    2:18p ET 03/27/23
  • Last (size)
  • 52-Wk Range
    2.32 - 28.40
  • (04/04/22 - 12/28/22)
  • 162.2%
  • Market Cap
  • Shares Outstanding
  • -40.43
  • --
  • No dividend
  • Ex-dividend Date
    No dividend
  • Dividend Pay Date
    No dividend
  • 0.0
  • 12.57
  • (% of float 02/28/23)

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.